Received May 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
She experienced myalgia, fatigue and headache for ~1.5 days.; She experienced myalgia, fatigue and headache for ~1.5 days.; She experienced myalgia, fatigue and headache for ~1.5 days.; This spontaneous report was received from a Nurse Practitioner and refers to a 5-decade-old (reported as in her 40's) female adult patient. The patient's concurrent conditions included autoimmune disease. Her pertinent medical history, concomitant therapies, previous drugs reactions and allergies were not reported. On an unknown date, the patient was vaccinated with one dose of pneumococcal 21-valent conjugate vaccine (CAPVAXIVE) administered intramuscularly as prophylaxis (Lot No., expiration date, strength, dose number, exact dose quantity volume, anatomical location of administration and vaccination scheme frequency were not provided). On an unknown day in approximately February 2026 (reported as 3 months ago), the patient experienced myalgia, fatigue and headache (headache) (fatigue) (myalgia). On an unspecified day in approximately February 2026 (reported as for ~1.5 days), the patient recovered from all the events. The causal relationship between all the events with pneumococcal 21-valent conjugate vaccine (CAPVAXIVE) was not provided. Lot # is being requested and will be submitted if received.
Autoimmune disorder